CERO THERAPEUTICS HOLDINGS INC
For the period ended Dec 31, 2023. Filed Apr 2, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 2, 2024
CERO$0.00-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(2,536,233) | $(667,736) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Interest income earned on marketable securities held in Trust Account | (491,571) | (2,836,864) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 197,762 | 254,831 |
| Income tax payable | (575,526) | 599,159 |
| Accounts payable and accrued expenses | 1,881,964 | 1,638,687 |
| Franchise tax payable | - | (80,324) |
| Net cash used in operating activities | (1,523,604) | (1,092,247) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Cash withdrawn from Trust Account for taxes | 752,300 | 144,544 |
| Investment of restricted cash into marketable securities in the Trust Account | (14,335,919) | (325,000) |
| Cash withdrawn from Trust Account in connection with Class A common stock redemption | 5,638,879 | 181,019,852 |
| Net cash provided by investing activities | (7,944,740) | 180,839,396 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from promissory note - related party | 905,000 | 650,000 |
| Redemption of Class A common stock | (33,481,627) | (139,353,878) |
| Net cash used in financing activities | (32,576,627) | (138,703,878) |
| NET CHANGE IN CASH AND RESTRICTED CASH | (42,044,971) | 41,043,271 |
| CASH AND RESTRICTED CASH, BEGINNING OF PERIOD | 42,141,844 | 1,098,573 |
| CASH AND RESTRICTED CASH, END OF PERIOD | $96,873 | $42,141,844 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $670,345 | $— |
| Supplemental disclosure of noncash activities: | ||
| Accretion of Class A common stock subject to possible redemption | $606,346 | $2,662,553 |
| Shareholder redemption liability | $— | $27,842,747 |
| Conversion of Class B common to Class A common | $(459) | $— |
| Excise tax liability accrued for Class A common stock redemptions | $56,389 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.